Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6987009 | 0.92 | ACHE (1.00) | ACHEBCHE | |
| SCHEMBL9411281 | 0.89 | ACHE (0.80) | ACHEBCHE | |
| SCHEMBL9411421 | 0.88 | ACHE (0.78) | ACHEBCHE | |
| Fumaric Acid SCHEMBL6989655 | 0.85 | ACHE (0.86) | ACHEBCHE | |
| SCHEMBL9411373 | 0.85 | ACHE (0.74) | ACHEBCHE | |
| Maleic Acid SCHEMBL6987328 | 0.85 | ACHE (0.86) | ACHEBCHE | |
| SCHEMBL9411460 | 0.85 | ACHE (0.74) | ACHEBCHE | |
| SCHEMBL9411227 | 0.85 | ACHE (0.74) | ACHEBCHE | |
| SCHEMBL9411614 | 0.85 | ACHE (0.74) | ACHEBCHE | |
| SCHEMBL9411499 | 0.85 | ACHE (0.74) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| EP-0646115-B1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2003-01-22 | — | — | EP | claimed |
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ZORN STEVIN H (US) | 2002-05-02 | — | — | US | claimed |
| EP-1201268-A2 | Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| US-20020028834-A1 | Heterocyclic-cyclic amine derivatives | VILLALOBOS ANABELLA (US) | 2002-03-07 | — | — | US | claimed |
| US-6326382-B1 | CHOLINESTERASE INHIBITORS; USEFUL IN ENHANCING MEMORY IN PATIENTS SUFFERING FROM DEMENTIA AND ALZHEIMER'S DISEASE | EISAI CO., LTD (JP) | 2001-12-04 | — | — | US | claimed |
| JP-2659107-B2 | — | EISAI CO LTD (JP) | 1997-09-30 | — | — | JP | claimed |
| EP-0646115-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-04-05 | — | — | EP | claimed |
| EP-0602242-A1 | BENZISOXAZOLE COMPOUND AND USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-06-22 | — | — | EP | claimed |
| WO-1992017475-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | PFIZER INC. (US) | 1992-10-15 | — | — | WO | claimed |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| EP-1910385-B1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-6326382-B1 | CHOLINESTERASE INHIBITORS; USEFUL IN ENHANCING MEMORY IN PATIENTS SUFFERING FROM DEMENTIA AND ALZHEIMER'S DISEASE | EISAI CO., LTD (JP) | 2001-12-04 | — | — | US | disclosed |
| US-5538984-A | Methods of using piperidyl-benzisoxazole and benisothiazole derivatives as cholinesterase inhibitors | PFIZER INC. (US) | 1996-07-23 | — | — | US | disclosed |
| EP-0646115-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-04-05 | — | — | EP | disclosed |
| EP-0602242-A1 | BENZISOXAZOLE COMPOUND AND USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| WO-1992017475-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | PFIZER INC. (US) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ACHE, BCHE, CHRM4 | ACHE 1/4885BCHE 2/4885 |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | NNT, CS, ME2 | ACHE 4624/4885BCHE 2692/4885 |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | ACHE 27/4885BCHE 48/4885 |
| US-20020028834-A1 | Heterocyclic-cyclic amine derivatives | BCHE, ACHE, CHRM1 | ACHE 2/4885BCHE 1/4885 |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | NNT, CS, ME2 | ACHE 4624/4885BCHE 2692/4885 |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | ACHE 1600/4885BCHE 3010/4885 |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | ACHE 1600/4885BCHE 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.